Company intelligence / Profile preview

RNatives

Ownership: Private
Employees: ~10
Development stage: Preclinical

Overview

RNatives has demonstrated proof-of-concept in vivo using promoter-targeted small hairpin RNAs that activate VEGFA expression leading to neovascularization and recovery in animal models of hindlimb ischemia and myocardial infarction. These findings are supported by multiple peer-reviewed publications from their founder Mikko Turunen’s academic research since mid-late 2000s[1].

Therapeutic areas: CardiovascularNeurology
Modalities: Small RNA therapeutics (nuclear microRNAs, small hairpin RNAs)RNA activation drugs / gene therapy modalities targeting endogenous gene expression modulation
Industry: Biotech

Beyond the preview

Go deeper on RNatives.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RNatives.

Explore the full profile